Cite

HARVARD Citation

    Nellan, A. et al. (2018). Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. Journal for immunotherapy of cancer. 6 (1), p. . [Online]. 
  
Back to record